Our patient experienced apathy without somnolence, hypomania, or extrapyramidal side effects after about 1 month of sertraline therapy. The apathy symptom appeared to be dose-related, and diminished rapidly after the sertraline dosage was decreased. Not only was her apathy diminished, but the improvement in her symptoms of panic disorder persisted even after the SSRI dosage was decreased. Moreover, there were no other causes to induce apathy, such as consciousness disturbance, cognitive impairment, drug use, frontal lobe lesion, or hyperthyroidism.3,5 The characteristics of the apathy syndrome induced by sertraline in our case were similar to those in the literature about SSRI-induced apathy syndrome. Although the apathy syndrome induced by SSRIs is frequently unrecognized, as this phenomenon is delayed in onset and subtle, clinicians must be careful to watch for signs of this syndrome after initiating sertraline treatment for patients with panic disorder or depressive disorder.